Sustained disease control with aflibercept 8 mg: A turning point in the management of exudative retinal disease: Expert consenus. Ukr. j. ophthalmol. [Internet]. 2026 Apr. 27 [cited 2026 Aug. 9];(2):71-6. Available from: https://ua.ozhurnal.com/index.php/files/article/view/712